{"resourceType": "Bundle", "id": "1", "type": "collection", "entry": [{"resource": {"resourceType": "Patient", "id": "1", "name": [{"use": "official", "family": "Ritchie", "given": null, "prefix": ["Mrs."]}, {"use": "maiden", "family": "Towne", "given": ["Opal", "Thomasina"], "prefix": ["Mrs."]}], "telecom": null, "gender": "female", "birthDate": null, "address": null, "maritalStatus": null, "multipleBirthBoolean": false, "communication": null}}, {"resource": {"resourceType": "Immunization", "id": "2", "status": "unknown", "vaccineCode": {"coding": [{"system": "http://hl7.org/fhir/sid/cvx", "code": "207", "display": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose"}], "text": "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose"}, "patient": {"reference": "Patient/1"}, "occurrenceDateTime": null, "primarySource": true, "occurrenceString": "2021-10-19T11:24:38+02:00"}}]}
This clinical note pertains to Mrs. Ritchie, formerly known as Mrs. Opal Thomasina Towne. She is female and does not have multiple births to her name. 

Mrs. Ritchie was administered the SARS-COV-2 (COVID-19) vaccine, which specifically used the mRNA spike protein LNP without any preservatives. The delivered dosage was 100 mcg in a 0.5mL solution. It's worthwhile noting that this immunization data primarily originated from the vaccine manufacturer's records. 

Although the exact status of the immunization is at present unknown, she received this dose on the 19th of October, 2021, at 11:24:38 in her local timeline, observing a GMT+02:00. 

This brief aims to encapsulate Mrs. Ritchie's medical information, particularly focusing on her COVID-19 immunization details. More detailed follow-ups may be necessary in light of the unknown current status of her vaccination.
This clinical note pertains to XXXXXXX. XXXXXXX, formerly known as XXXXXXX. XXXXXXXXXXXXXX. XXXXXXX is XXXXXXX and does not have multiple births to XXXXXXX name. 

XXXXXXX. XXXXXXX was administered the SARS-COV-2 (COVID-19) vaccine, which specifically used the mRNA spike protein LNP without any preservatives. The delivered dosage was 100 mcg in a 0.5mL solution. It's worthwhile noting that this immunization data primarily originated from the vaccine manufacturer's records. 

Although the exact status of the immunization is at present unknown, XXXXXXX received this dose on the XXXXX, at XXXXXin XXXXXXX local timeline, observing a GMT+XXXXX. 

This brief aims to encapsulate XXXXXXX. XXXXXXX's medical information, particularly focusing on XXXXXXX COVID-19 immunization details. More detailed follow-ups may be necessary in light of the unknown current status of XXXXXXX vaccination.